
doi: 10.1136/dtb.29.16.61
In October 1988 a combined measles/mumps/rubella (MMR) vaccine replaced the single measles vaccine in Britain with the aim of eliminating all three diseases as well as the congenital rubella syndrome. The Department of Health recommends that, barring contraindications, MMR immunisation should be given to all children aged 12–15 months and should be offered to older unimmunised children preferably before they start school. The three products now available are Pluserix MMR (Smith Kline Beecham), MMR-II (Wellcome) and Immravax (Merieux).
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
